Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146M | $165M | $193M | $227M | $248M | $269M | $254M | $193M | $199M | $216M |
| Revenue growth | — | 13.1% | 17.0% | 17.6% | 9.2% | 8.3% | -5.3% | -24.3% | 3.2% | 8.7% |
| Operating income | -$18.6M | -$16.9M | $21.7M | $22.8M | $27.2M | $42.2M | $6.33M | -$14.0M | -$40.7M | -$151M |
| Operating margin | -12.7% | -10.2% | 11.3% | 10.0% | 11.0% | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Net income | -$18.0M | -$15.6M | $25.2M | $116M | $23.3M | $33.2M | $6.28M | $2.51M | -$18.9M | -$220M |
| Net margin | -12.3% | -9.4% | 13.1% | 50.9% | 9.4% | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% |
| EPS (diluted) | -$0.41 | -$0.35 | $0.48 | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | -$0.33 | -$3.74 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.10M | -$1.98M | $30.0M | $45.9M | $51.8M | $64.2M | $32.0M | $12.8M | -$15.8M | -$109M |
| Capital expenditures | $1.41M | $1.66M | $368K | $1.02M | $1.79M | $552K | $679K | $383K | $490K | $998K |
| Free cash flow | -$9.51M | -$3.65M | $29.6M | $44.9M | $50.0M | $63.7M | $31.3M | $12.4M | -$16.2M | -$110M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $40.4M | $33.6M | $61.0M | $45.1M | $61.0M | $52.1M | $135M | $136M | $102M | $84.9M |
| Total assets | $210M | $205M | $332M | $484M | $533M | $594M | $634M | $648M | $656M | $489M |
| Total liabilities | $79.0M | $74.0M | $56.7M | $72.8M | $80.2M | $88.9M | $107M | $104M | $118M | $162M |
| Shareholders' equity | $131M | $131M | $275M | $411M | $453M | $505M | $527M | $545M | $539M | $327M |
| Retained earnings | -$346M | -$361M | -$336M | -$221M | -$197M | -$164M | -$158M | -$155M | -$174M | -$395M |
| Shares (wtd avg diluted) | 43.4M | 44.7M | 53.0M | 54.8M | 55.2M | 56.9M | 57.0M | 57.6M | 58.1M | 58.9M |
Every figure is extracted from Vanda Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.